Esophageal Doppler monitor EDM

Minimal Change Disease

Antibody Drug Conjugates ADC

The humanized anti-Her2 monoclonal antibody Herceptin (trastuzumab) has become the mainstay in the treatment of Her2-positive breast cancer. Combining trastuzumab with the potent cytotoxic DM1 via a s...

Kadcyla (ado-trastuzumab emtansine)

Kadcyla™ (ado-trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin® (trastuzumab)...

Telehealth

Telehealth uses communication devices such as computers, mobiles and tablets to deliver healthcare. For example, many patients monitor their condition using a telehealth computer which can take read...

NRC, AvidBiologics partner to develop three novel ADCs for treatment of cancer

AvidBiologics Inc., a life sciences company developing antibody-drug conjugates (ADCs), announces the conclusion of an agreement with the National Research Council Canada (NRC) to develop three novel...

Fujifilm Diosyn, Piramal partner for ADCs production

Fujifilm Diosynth Biotechnologies has entered into a partnership with Piramal Healthcare UK for production of antibody drug conjugates (ADCs).

Astellas in biotech partnering with Ambrx for ADCs

Astellas , a top 50 big pharma, entered into a biotech partnering with Ambrx  for the discovery and development of novel antibody drug conjugates. ADCs allow for the targeted delivery of drugs to the...

ADCs Clear Another Hurdle as Adcetris Gains EU Approval

Backers of ADCs have more good news coming from Europe today as the EU approves Adcetris for use in the treatment of relapsesed Hodgkin's and ALCL. Millennium (Takeda) licensed rights to sell the prod...

Pharmaceutical Research: Pharmacokinetic Considerations for Antibody Drug Conjugates

Type: Review PaperAntibody drug conjugates (ADCs) are a class of therapeutics that combine the target specificity of an antibody with the potency of a chemotherapeutic. This therapeutic strategy can s...

Astellas and Ambrx initiate collaboration for discovery and development of antibody drug conjugates for oncology

Astellas Pharma Inc. (Tokyo: 4503, "Astellas") entered into a collaboration with Ambrx Inc. ("Ambrx") for the discovery and development of novel antibody drug conjugates ("ADCs"). ADCs allow for the t...

Catalent Biologics expands into ADCs through license with Redwood Bioscience

Catalent Pharma Solutions has acquired an exclusive license to market Redwood Bioscience's proprietary SMARTag precision protein-chemical engineering technology for the development of advanced antibod...

The AAPS Journal: ADME of Antibody–Maytansinoid Conjugates

Type: Original PaperThe concept of treating cancer with antibody-drug conjugates (ADCs) has gained momentum with the favorable activity and safety of trastuzumab emtansine (T-DM1), SAR3419, and lorvot...

Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.

Aim:  The cholinesterase inhibitor rivastigmine is available in both oral and transdermal forms. The efficacy of oral rivastigmine appears to be dose-dependent. The current analysis investigates the...

Pharmacokinetic Considerations for Antibody Drug Conjugates.

Antibody drug conjugates (ADCs) are a class of therapeutics that combine the target specificity of an antibody with the potency of a chemotherapeutic. This therapeutic strategy can significantly expan...

ADC measurements in the evaluation of lymph nodes in patients with non-Hodgkin lymphoma: feasibility study.

OBJECT: To determine whether apparent diffusion coefficient (ADC) measurements allow discrimination of normal lymph nodes from lymphomatous lymph nodes, and indolent lymphomas from aggressive lymphoma...

The synthesis of pABA: coupling between the glutamine amidotransferase and aminodeoxychorismate synthase domains of the bifunctional aminodeoxychorismate synthase from Arabidopsisthaliana.

Aminodeoxychorismate (ADC) synthase in plants is a bifunctional enzyme containing glutamine amidotransferase (GAT) and ADC synthase (ADCS) domains. The GAT domain releases NH(3) from glutamine and the...

Bone Metastases from Prostate Cancer: Assessing Treatment Response by Using Diffusion-weighted Imaging and Functional Diffusion Maps--Initial Observations.

Purpose: To prospectively investigate and monitor the response to antiandrogen treatment of bone metastases in patients with prostate cancer by using diffusion-weighted (DW) magnetic resonance (MR) im...